AKR1B10 Drives Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing Ferroptosis via NQO1/GPX4 Axis
Journal of Gastroenterology and Hepatology · 2026-10 · 41 (10) · 3209-3223
DOI: 10.1111/jgh.70670 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 16.08.2026. Verfasst von Jiahao Jiang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province, China. Hauptthemen laut MEDLINE: Quinolines, Ferroptosis, Phenylurea Compounds, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Guangzhou Municipal Science and Technology Project.
Abstract (Originalsprache)
Background
Lenvatinib is utilized as a first‐line therapy for hepatocellular carcinoma (HCC); however, the emergence of resistance significantly impairs its clinical efficacy. Ferroptosis, a newly recognized form of cell death, has been implicated in tumor progression and treatment resistance. This study investigates the interaction between ferroptosis and lenvatinib resistance in HCC and explores the underlying mechanisms.
Methods
A lenvatinib‐resistant cell line was established, combined with multiplex transcriptome sequencing and external bioinformatics analysis to identify key resistance genes. The biological functions of lenvatinib resistance were validated through assays of cell viability, colony formation, apoptosis, and xenograft models. Ferroptosis effects were analyzed using assays such as transmission electron microscopy (TEM), C11‐BODIPY staining, malondialdehyde (MDA) measurement, and Fe 2+ detection. Furthermore, KEGG pathway enrichment analysis, Western blotting, immunofluorescence colocalization, and immunohistochemistry were conducted to explore the underlying mechanisms.
Results
Transcriptome sequencing combined with in vitro and in vivo experiments revealed that AKR1B10 was significantly downregulated following short‐term lenvatinib treatment, but was upregulated with the induction of resistance. Knockdown of AKR1B10 markedly reversed acquired resistance to lenvatinib. Furthermore, we found that the upregulation of AKR1B10 substantially inhibited lenvatinib‐induced ferroptosis. Mechanistically, the NQO1/GPX4 axis was identified as the downstream signaling pathway through which AKR1B10 regulates ferroptosis. Notably, overexpression of NQO1 effectively restored both ferroptosis and sensitization to lenvatinib induced by AKR1B10 knockdown.
Conclusions
This study reveals that AKR1B10 inhibits ferroptosis in HCC through the NQO1/GPX4 axis, promoting acquired resistance to lenvatinib. These findings suggest that AKR1B10 could be a novel therapeutic target for overcoming lenvatinib resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province, China.
- Guangdong Provincial key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province, China.
- Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, Hunan Province, China.
- Department of General Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
- Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
ORCID-Profile: Jiahao Jiang, Zhiqin Xie, Changzhen Shang
Förderung
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Guangzhou Municipal Science and Technology Project
Zitieren
APA
Jiang, J., Wang, B., Wang, Q., Ma, X., Xie, Z., Yang, L., Tang, C., Zhuang, H., Wang, W., Shang, C., & Chen, Y. (2026). AKR1B10 Drives Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing Ferroptosis via NQO1/GPX4 Axis. Journal of Gastroenterology and Hepatology, 41(10), 3209-3223. https://doi.org/10.1111/jgh.70670
Vancouver
Jiang J, Wang B, Wang Q, Ma X, Xie Z, Yang L, et al. AKR1B10 Drives Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing Ferroptosis via NQO1/GPX4 Axis. Journal of Gastroenterology and Hepatology. 2026;41(10):3209-3223. doi:10.1111/jgh.70670
BibTeX
@article{Jiang2026,
author = {Jiang, Jiahao and Wang, Bingkun and Wang, Qingbin and Ma, Xiaowu and Xie, Zhiqin and Yang, Lei and Tang, Chenwei and Zhuang, Hongkai and Wang, Wentao and Shang, Changzhen and Chen, Yajin},
title = {AKR1B10 Drives Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing Ferroptosis via NQO1/GPX4 Axis},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
volume = {41},
number = {10},
pages = {3209--3223},
doi = {10.1111/jgh.70670}
}
EUVIMED